N/A
Completed N=685
Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
Source: ClinicalTrials.gov NCT04738643 ↗Enrolled (actual)
685
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Intervention Ordering Rate — 113; 60 Participants
Summary
The research objective is to identify a simple, pragmatic, innovative way of enhancing Tobacco Use Treatment (TUT) rates within oncology. To investigate this possibility, the investigators propose methods that will allow them to: 1) evaluate the impact of standing orders to initiate a varenicline management protocol within outpatient cancer treatment workflow, 2) assess the potential for an EHR-based intervention to affect patient TUT behaviors, and 3) identify important facilitators and barriers that impact effectiveness of the intervention.
The investigators will assess whether including a standing order for prescription and management of varenicline (TUT Service+VM) within the workflow for cancer patients identified as current smokers will significantly increase TUT engagement rates compared to current standard of care (TUT Service alone). The investigators hypothesize that observed treatment engagement rates will be higher among clinicians exposed to TUT Service+VM than observed in clinicians exposed to TUT Service alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intervention Ordering Rate |
113; 60 | — |
| SECONDARY Inpatient Medication Ordering Rate |
73; 41 | — |
| SECONDARY Outpatient/Discharge Medication Ordering Rate |
26; 17 | — |
| SECONDARY TUTS Referral Rate |
13; 20 | — |
| SECONDARY Quit Line Rate |
5; 5 | — |
| SECONDARY Medication Recommendation Rate |
4; 4 | — |
| SECONDARY Follow-up Recommendation Rate |
4; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Currently in active practice within Medical and Radiation Oncology divisions of ACC,
- Prescribing authority in Pennsylvania (i.e. physician, nurse practitioner, physician assistant),
- Nonsmoker,
- Has cared for at least one patient with tobacco use disorder in the 30 days prior to recruitment,
- English speaking, and
- Willing to provide informed consent to participate.
Exclusion Criteria
- Unwillingness to prescribe varenicline, or
- Unwillingness to assign varenicline management to TUT Service providers.
Data sourced from ClinicalTrials.gov (NCT04738643). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.